Scilex Holding Company earnings releases SCLX

Annual Quarterly

Scilex Holding Company last reported quarterly results on Oct 8, 2024, for Q3 FY2024 (the quarter ended Sep 30, 2024): revenue of $14.4 million (+42.7% year over year) and diluted EPS of -$0.58. It usually reports 1–16 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–16 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Oct 8, 2024
8 days after quarter end
Q3 FY2024
ended Sep 30, 2024
14
+42.7%
-4
+87.6%
-0.58
+7.9%
Jul 1, 2024
1 days after quarter end
—
ended Jun 30, 2024
—
—
—
Apr 16, 2024
16 days after quarter end
—
ended Mar 31, 2024
—
—
—
Jan 2, 2024
2 days after quarter end
—
ended Dec 31, 2023
—
—
—
Oct 2, 2023
2 days after quarter end
—
ended Sep 30, 2023
—
—
—
Jul 5, 2023
5 days after quarter end
—
ended Jun 30, 2023
—
—
—
Apr 3, 2023
3 days after quarter end
—
ended Mar 31, 2023
—
—
—
Jan 3, 2023
3 days after quarter end
—
ended Dec 31, 2022
—
—
—

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SCLX (Nasdaq), SCLXW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
1820190
Former names
Scilex Holding Company/DE (until Nov 30, 2022); Vickers Vantage Corp. I (until Nov 15, 2022)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.